The preparations of novel tridentate C,N,S-donor ligand precursors, PhN=C(CMe 2 )(NPh)C=N(CH 2 ) 2 SR [R = CMe 3 (2); R = Ph (3)] are described. Treatment of 2 and 3 with 1 equiv. of Pd(OAc) 2 affords the orthometallated palladium(II) complexes [PhN=C(CMe 2 )(N-η 1 -Ph)C=N(CH 2 ) 2 SR]Pd(OAc) [R = CMe 3 (4); R = Ph (5)]. Reaction of 4 and 5 with an excess of LiCl in methanol affords the orthometallated palladium(II)[a] 4642 complexes [PhN=C(CMe 2 )(N-η 1 -Ph)C=N(CH 2 ) 2 SR]PdCl [R = CMe 3 (6); R = Ph (7)]. Crystal structures are reported for compounds 3 and 4. The application of these novel palladacyclic complexes as catalyses for the Suzuki and Heck reactions with aryl halide substrates was examined. (
A range of stable emulsions of spherical
and rod-like conjugated
polymer nanoparticles (CPN) were synthesized via Suzuki−Miyaura
cross-coupling reactions of 9,9-dioctylfluorene-2,7-diboronic acid
bis(1,3-propanediol) ester with a number of different dibromoarene
monomers in xylene, stabilized in water by the nonionic surfactant,
Triton X-102. High molar mass poly(9,9-dioctylfluorene) (PF8), poly(9,9-dioctylfluorene-alt-benzothiadiazole) (PF8BT), poly(9,9-dioctylfluorene-alt-4-sec-butylphenyldiphenylamine) (PF8TAA)
and poly(9,9-dioctylfluorene-alt-bithiophene) (PF8T2)
emulsions were obtained, at high overall conjugated polymer concentrations
(up to 11,000 ppm), in the presence of the palladium complex, (IPr*)PdCl2(TEA) and base, tetraethylammonium hydroxide, in nitrogen
atmosphere at 30 °C after 24–48 h. TEM analysis of the
PF8 and PF8T2 emulsions revealed regular rod-like structures, up to
200 nm in length with aspect ratios of 4–5. PF8BT and PF8TAA
formed spherical particles with diameters of between 20–40
nm in TEM analysis. UV–vis absorption spectra of the PF8 emulsions
indicated high levels of ordered β-phase configuration (9–10%)
in their respective nanoparticles. Absolute photoluminescence quantum
yields (Φ) of 21–25% were recorded for these emulsions.
The use of well-defined (N-heterocyclic carbene)-Ag(I) complexes for the A(3) reaction allows for the coupling of unactivated aldehydes at room temperature and very short reaction times.
A general protocol for the Sonogashira reaction using a 100:1 combination of (N-heterocyclic carbene)-Cu and (N-heterocyclic carbene)-Pd complexes is presented. Catalyst loadings of 1 mol % (NHC)-Cu and 0.01 mol % (NHC)-Pd allow for the coupling of aryl bromides and aryl alkynes, in air and in a non-anhydrous solvent, in high yields.
Three new anilido-oxazolines, ortho-C(6)H(4)(NHAr')(4,4-dimethyl-2-oxazoline) [Ar'=2,4,6-trimethylphenyl, HNPh(TriMe)Oxa (1); 2,6-diisopropylphenyl, HNPh(DiiPr)Oxa (2); 2-methoxyphenyl, HNPh(OMe)Oxa (3)], have been prepared. Reactions of 1 or 2 with one molar equivalent of ZnEt(2) in tetrahydrofuran or hexane solution give the zinc ethyl complexes (NPh(TriMe)Oxa)ZnEt (4) and (NPh(DiiPr)Oxa)ZnEt (5). The dinuclear zinc benzyloxide complexes, [(NAr'Oxa)Zn(mu-OBn)](2), [Ar'=2,4,6-trimethylphenyl, (6); 2-methoxyphenyl, (7)], were synthesized by the reaction of 4 with one molar equivalent of benzyl alcohol in tetrahydrofuran solution (for 6) or by treatment of with 3 one molar equivalent of ZnEt(2) in tetrahydrofuran solution followed by the addition of one molar equivalent of benzyl alcohol (for 7). The molecular structures are reported for compounds 6 and 7. Their catalytic activities toward the ring opening polymerization reactions are under investigation.
Preparations of novel unsymmetrical, tridentate nitrogen ligand precursors, PhN=C(CMe2)(NPh)C=N(CH2)2NMe2(1) and PhN=C(CMe2)(NPh)C=N(CH2)Py (2), are described. Treatment of 1 with 1 molar equiv. (COD)PdCl2 in the presence of NEt3 or with 1 molar equiv. Pd(OAc)2 affords orthometallated palladium(II) complexes, [PhN=C(CMe2)(N-eta1-Ph)C=N(CH2)2NMe2]PdX (X=Cl (3); X=OAc (4)), respectively. Compound can be yielded via the reaction of with an excess of LiCl in methanol. Treatment of with 1 molar equiv. of (COD)PdCl2, Pd(OAc)2 or Pd(TFA)2 affords orthometallated palladium(II) complexes, [PhN=C(CMe2)(N-eta1-Ph)C=NCH2Py]PdX (X=Cl (5); X=OAc (6); X=TFA (7)), respectively. The crystal and molecular structures are reported for compounds 2, 3, 5 and 6. The application of these novel palladacyclic complexes to the Heck reaction with aryl halide substrates was examined.
The synthesis, structural characterization, and reactivity studies of titanium complexes supported by tridentate amine biphenolate ligands of the type [RN(CH(2)-2-O-3,5-C(6)H(2)(tBu)(2))(2)](2-) {[R-ONO](2-); R = tBu (1a), iPr (1b), nPr (1c)} are described. Alcoholysis of Ti(OiPr)(4) with H(2)[1a-1c] in diethyl ether solutions at 25 °C generates quantitatively the corresponding [R-ONO]Ti(OiPr)(2) (2a-2c) as a yellow crystalline solid. X-ray diffraction studies of 2b and 2c showed them to be five-coordinate, trigonal-bipyramidal species. Ring-opening polymerization of ε-caprolactone (ε-CL) catalyzed by 2b and 2c proved to be living, as evidenced by the narrow molecular weight distributions of the derived polymers and the linear dependence of number-averaged molecular weights on the monomer-to-catalyst ratios or polymerization time. Kinetic studies revealed that the polymerization rates are first-order in the concentration of ε-CL and first-order in that of 2b and 2c. The propagation rate of 2c is ca. 15 times faster than that of 2b, highlighting a profound substituent effect of primary versus secondary N-alkyls. In sharp contrast, reactions employing catalytic 2a produce either low-molecular-weight oligomers or polymers characteristic of somewhat wider molecular weight distributions, depending on the polymerization temperatures.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.